SciClone Pharmaceuticals Inc. (SCLN) Shares Down 2.5%
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) was down 2.5% on Friday . The stock traded as low as $10.23 and last traded at $10.39, with a volume of 383,783 shares traded. The stock had previously closed at $10.66.
The firm has a market capitalization of $519.86 million and a PE ratio of 14.05. The firm has a 50 day moving average of $11.74 and a 200 day moving average of $11.47.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter. The company had revenue of $39 million for the quarter, compared to analysts’ expectations of $37.90 million. Equities analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.
An institutional investor recently raised its position in SciClone Pharmaceuticals stock. Cornerstone Capital Management Holdings LLC. increased its stake in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 32.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 198,570 shares of the specialty pharmaceutical company’s stock after buying an additional 48,470 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.40% of SciClone Pharmaceuticals worth $1,827,000 as of its most recent filing with the SEC.
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.